Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$80.79 USD

80.79
9,982,882

+0.93 (1.16%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $80.91 +0.12 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback

AZN and BAYRY announce Q3 results. ABBV's studies on schizophrenia candidate, emraclidine, fail to meet goal.

Zacks Equity Research

Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy

MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.

Zacks Equity Research

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.

Sweta Killa headshot

Stocks and ETFs in Focus as Americans Head to Polls

Let's discuss the sectors and ETFs that are the potential gainers or losers as Americans head to the polls, which indicate a tight race between Harris and Trump.

Sundeep Ganoria  headshot

Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus

LLY, MRK, PFE, ABBV and NVS announce report third-quarter results.

Zacks Equity Research

Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil vaccines.

Zacks Equity Research

Merck (MRK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales

SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.

Zacks Equity Research

Merck (MRK) Q3 Earnings and Revenues Top Estimates

Merck (MRK) delivered earnings and revenue surprises of 4.67% and 0.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook

EXEL tops on earnings and sales in the third quarter as lead drug Cabometyx maintains momentum. The company also raises its revenue guidance for 2024.

Zacks Equity Research

Eli Lilly (LLY) Lags Q3 Earnings and Revenue Estimates

Lilly (LLY) delivered earnings and revenue surprises of -22.37% and 4.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?

Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.

Zacks Equity Research

Exploring Analyst Estimates for Merck (MRK) Q3 Earnings, Beyond Revenue and EPS

Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Kinjel Shah headshot

Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?

Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.

Zacks Equity Research

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

Zacks Equity Research

Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?

Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.

Zacks Equity Research

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Equity Research

Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?

The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.

Zacks Equity Research

Merck (MRK) Advances While Market Declines: Some Information for Investors

Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close.

Zacks Equity Research

The Zacks Analyst Blog Highlights Visa, Netflix, Merck and Hovnanian

Visa, Netflix, Merck and Hovnanian are included in this Analyst Blog.

Mark Vickery headshot

Top Research Reports for Visa, Netflix & Merck

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Netflix, Inc. (NFLX) and Merck & Co., Inc. (MRK), as well as a micro-cap stock Hovnanian Enterprises, Inc. (HOV).

Kinjel Shah headshot

Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.